CN115350199A - Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth - Google Patents
Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth Download PDFInfo
- Publication number
- CN115350199A CN115350199A CN202210926222.0A CN202210926222A CN115350199A CN 115350199 A CN115350199 A CN 115350199A CN 202210926222 A CN202210926222 A CN 202210926222A CN 115350199 A CN115350199 A CN 115350199A
- Authority
- CN
- China
- Prior art keywords
- injection
- tissue
- formula
- scar tissue
- dissolving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 33
- 239000003102 growth factor Substances 0.000 title claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 230000012010 growth Effects 0.000 title claims abstract description 11
- 206010020718 hyperplasia Diseases 0.000 title abstract description 13
- 239000007924 injection Substances 0.000 claims abstract description 38
- 238000002347 injection Methods 0.000 claims abstract description 38
- 229940090044 injection Drugs 0.000 claims abstract description 35
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims abstract description 19
- 229960002117 triamcinolone acetonide Drugs 0.000 claims abstract description 15
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 12
- 229960002537 betamethasone Drugs 0.000 claims abstract description 8
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 229940025300 lidocaine injection Drugs 0.000 claims abstract description 8
- 229940081995 fluorouracil injection Drugs 0.000 claims abstract description 7
- 229940089602 epinephrine injection Drugs 0.000 claims abstract description 6
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 26
- 206010063560 Excessive granulation tissue Diseases 0.000 abstract description 10
- 210000001126 granulation tissue Anatomy 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 238000011282 treatment Methods 0.000 description 8
- 208000032544 Cicatrix Diseases 0.000 description 5
- 208000002260 Keloid Diseases 0.000 description 5
- 206010023330 Keloid scar Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 210000001117 keloid Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- HYKGUEIYMKVUSR-NPULLEENSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C HYKGUEIYMKVUSR-NPULLEENSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000703 anti-shock Effects 0.000 description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- YTYBKUMQBAPTAX-UHFFFAOYSA-N carbonic acid;2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide Chemical compound OC(O)=O.OC(O)=O.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C YTYBKUMQBAPTAX-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth, which acts on granulation tissue, scar tissue and fibrous tissue, and comprises the following components in part by weight: 0.5ml-2ml of triamcinolone acetonide injection; 0.5ml-2ml of compound betamethasone injection; 1ml-20ml of fluorouracil injection; 1ml-20ml of fluorouracil injection; dexamethasone injection 1ml-4ml; 1ml-10ml of lidocaine injection; 0.2ml-1ml of epinephrine injection; 1ml-16ml of physiological saline injection. The invention has the beneficial effects that: effectively inhibit and dissolve granulation tissue, scar tissue and fibrous tissue, can be kept for a long time, and is not easy to relapse.
Description
Technical Field
The invention relates to the field of medical treatment, in particular to a formula for dissolving scar tissues such as scar tissues, granulation tissues, fibrous tissues and the like of growth factor hyperplasia and inhibiting growth.
Background
The mechanisms of scar tissue, granulation tissue, and fibrous tissue formation are mainly the formation of excessive proliferation of fibrin and excessive deposition of collagen fibers. The appearance of abnormal mucopolysaccharides, as well as proliferation of myofibroblasts, leads to local swelling, stiffness, flushing, pain and itching due to imbalances in collagen synthesis and degradation. The tissues are very dense and tough, clothes compression can also cause pain and itching, and the patient scratching can further promote the hyperplasia of scars to cause vicious circle.
Scar tissue, granulation tissue and fibrous tissue are formed because the wound surface lacks a regulation mechanism in the healing process and the healed skin lacks protection, and the like, so that scars are generated. The important pathological changes of the hyperplastic scars are hyperplasia of blood vessels and collagen fibers and disordered arrangement, and the extreme itching of the skin is caused by the lack of oxygen of the microvascular wall in scar tissue and peripheral nerve endings thereof, but not caused by stimulation of the nerve endings on the surface of the skin.
At present, the methods for treating scar hyperplasia commonly use simple surgical excision, freezing or laser treatment, local' strontium application treatment of triamcinolone, deep X-ray radiotherapy after surgery or ionization operation and ointment or ointment application containing triamcinolone. Simple surgical resection, cryosurgery or laser treatment results in 100% recurrence. Some also cause skin damage or local pain, and the curative effect is not ideal. The simple topical injection of triamcinolone acetonide or the application of triamcinolone acetonide ointment or salve only can control the development of disease and relieve symptoms, which are not easy to cure. The effective rate of the strontium application treatment is less than 40 percent, and the deep X-ray radiotherapy after the operation or the electric ion operation has high effective rate but causes different degrees of damage to human bodies. At the same time, it is not used in the vicinity of the reproductive system of specific parts such as the chest line, children and infertile patients. Otherwise, serious consequences would be brought. The curative effect of the drug formula of the hyperplastic redundant tissues such as granulation tissues and proud flesh of redundant facial muscle tissues with more growth factors is insufficient, and the maintenance time is only 2-12 months.
Disclosure of Invention
Aiming at the technical problems, the invention provides a formula for dissolving scar tissues proliferated by growth factors and inhibiting growth, which is realized by the following technical scheme.
A formula for dissolving scar tissue proliferated by growth factor and inhibiting growth comprises the following components by weight:
0.5ml-2ml of triamcinolone acetonide injection;
0.5ml-2ml of compound betamethasone injection;
1ml-20ml of fluorouracil injection;
dexamethasone injection 1ml-4ml;
1ml-10ml of lidocaine injection;
0.2ml-1ml of epinephrine injection;
1ml-16ml of physiological saline injection.
Compared with the prior art, the invention has the beneficial effects that: effectively inhibit and dissolve granulation tissue, scar tissue and fibrous tissue, and has long drug effect time without relapse.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the present invention without making any creative effort, shall fall within the protection scope of the present invention.
A formula for dissolving scar tissue proliferated by growth factor and inhibiting growth mainly acts on granulation tissue, scar tissue and fibrous tissue with much growth factor, and the weight ratio is as follows:
0.5ml-2ml of triamcinolone acetonide injection;
0.5ml-2ml of compound betamethasone injection;
1ml-20ml of fluorouracil injection;
dexamethasone injection 1ml-4ml;
1ml-10ml of lidocaine injection;
0.2ml-1ml of epinephrine injection;
1ml-16ml of physiological saline injection. .
Triamcinolone acetonide is a medium-long-acting corticosteroid preparation with strong effect, and is commonly used for the injection treatment of scar and skin injury. Triamcinolone acetonide is the first choice medicine for clinical treatment of keloid at present, has powerful functions of inhibiting inflammation reaction and inhibiting proliferation of fibroblast in scar tissue, and can reduce the symptoms of tissue congestion, cell reaction, liquid exudation, etc. caused by non-infectious and infectious inflammation and inhibit the formation of granulation tissue and excessive growth of scar.
The relation between the concentration of triamcinolone acetonide and scar hyperplasia is not clear, and the dosage of triamcinolone acetonide in the existing method is relatively random and has no unified standard. If the concentration of triamcinolone acetonide is too low, the treatment effect cannot be achieved; if the concentration is too high, the medicine is retained for a long time, and complications such as leukoplakia, skin atrophy, pigmentation or hypofunction, telangiectasia or necrosis, ulcer or hypercortisolism and the like are caused.
In the process of treating keloid, triamcinolone acetonide is injected separately in large dose, which can cause the keloid to shrink and relieve the symptoms of pain, discomfort and the like, but the treated keloid has poor stability and easy recurrence, and has adverse reactions of menstrual disorder, obesity, acne and the like.
The diprospan compound betamethasone injection is a super-potent glucocorticoid, is a compound preparation consisting of betamethasone sodium phosphate with high solubility and betamethasone propionate with low solubility, and has stronger and more lasting anti-inflammatory and antiallergic effects. The diprospan can be maintained for 4 weeks, only 1 time of medication is needed per month, and the dosage or frequency of medication is reduced and the side effect is reduced due to long medication interval.
Dexamethasone injection belongs to adrenocortical hormone drugs, and has antiinflammatory, antiallergic, and antishock effects. The injection is added with dexamethasone injection, and has the effects of resisting inflammation, resisting allergy, resisting shock and immunosuppressing scar hyperplasia when being injected to an affected part.
A lidocaine injection is prepared from lidocaine hydrochloride and sodium bicarbonate by preparing sterilized aqueous solution of lidocaine carbonate under carbon dioxide saturation condition, wherein the local elimination of the medicine takes about 2 hr, and the addition of epinephrine can be prolonged to 4 hr.
In the embodiment of the invention, the treatment effect of the keloid is more stable and the effect is more durable by the combined use of a plurality of medicines. The incidence of adverse reactions of patients is obviously reduced.
Dexamethasone injection belongs to adrenocortical hormone drugs, and has antiinflammatory, antiallergic, and antishock effects. Also has immunosuppressive effect. The dexamethasone injection is added into the invention, and is mixed with other components, and when the dexamethasone injection is injected on an affected part, the dexamethasone injection has the effects of resisting inflammation, allergy and shock, inhibiting the immunity from scar hyperplasia, and effectively preventing the swelling and detumescence of drug reaction.
The application of lidocaine and epinephrine is to prevent itching of affected parts and scratching of patients when the lidocaine and epinephrine are used together with other medicines, so that the medication effect is prevented from being influenced.
Lidocaine has analgesic and analgesic effects, and epinephrine has effect in preventing hemorrhage, causing growth factor in blood, and causing swelling to result in more serious scar hyperplasia.
After the fluorouracil is added into the formula, scar tissues are obviously dissolved, active cell growth of the scar tissues is inhibited, and cell fission is prevented.
In the formula of the invention, the synergistic effect among the medicines overcomes the defects of random dosage and poor effect (easy relapse) in the prior art, can enhance the treatment effect, and can reduce the total usage amount of single medicine and the adverse reaction of the medicines in the formula.
The formulations of the present invention are further illustrated by the following examples.
The first embodiment is as follows:
a formula for dissolving scar tissue proliferated by growth factor and inhibiting growth comprises the following components by weight:
0.5ml of triamcinolone acetonide injection;
0.5ml of compound betamethasone injection;
5ml of fluorouracil injection;
4ml of dexamethasone injection;
5ml of lidocaine injection;
0.5ml of epinephrine injection;
5ml of physiological saline injection.
Example two
A formula for dissolving scar tissue proliferated by growth factor and inhibiting growth comprises the following components by weight:
1ml of triamcinolone acetonide injection;
1ml of compound betamethasone injection;
10ml of fluorouracil injection;
4ml of dexamethasone injection;
10ml of lidocaine injection;
0.5ml of epinephrine injection;
10ml of physiological saline injection.
150 volunteers were selected from 85 men, 65 women, 20-75 years of age on average, 40.21 + -7.07 years of age on average, all patients were randomly assigned to three groups, including triamcinolone acetonide group, one example group, and two example groups, with no statistical significance for comparison, difference in age, sex, course of disease, etc. (P > 0.05), for each group of 50 people, and are comparable, see tables 1-3.
In the triamcinolone acetonide group in the prior art, triamcinolone acetonide injection and 2% lidocaine injection are mixed according to a 1:1 ratio, and are injected on the surface of an affected part in points with a distance of 1cm, an injection amount of 0.1ml, a infiltration range of 0.5cm in diameter, and bound by gauze.
According to one group of embodiments of the invention, after the components are mixed according to the proportion of the first embodiment, the mixture is injected on the surface of an affected part in a point-to-point manner, the distance between points is 1cm, the injection amount is 0.1ml, the diameter of a infiltration range is 0.5cm, and the mixture is bound by gauze.
In the two groups of the embodiments of the invention, after being mixed according to the proportion of the second embodiment, the mixture is injected on the surface of an affected part in points, the distance between the points is 1cm, the injection amount is 0.1ml, the diameter of the infiltration range is 0.5cm, and the affected part is bound by gauze.
And (4) judging the standard: the healing is pain, pruritus disappears, scars are completely softened and flattened, the scars are soft to touch, no induration or cord marks exist, the recurrence does not occur within 12 months after healing, and 36 months are continuously observed.
Table 1: three general data comparisons
Table 2: comparison of three groups of clinical efficacy [ n (%) ]
Table 3: comparison of incidence of adverse reactions in three groups of patients [ n (%) ]
As can be seen from tables 1-3, the total effective rate of the clinical efficacy of the formulations of the present invention (including examples one and two) is significantly higher than that of the triamcinolone acetonide group, while the reject rate is significantly lower than that of the triamcinolone acetonide group.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the claims and their equivalents.
Claims (1)
1. A formula for dissolving scar tissue proliferated by growth factors and inhibiting growth is characterized in that the weight ratio is as follows:
0.5ml-2ml of triamcinolone acetonide injection;
0.5ml-2ml of compound betamethasone injection;
1ml-20ml of fluorouracil injection;
1ml-4ml of dexamethasone injection;
1ml-10ml of lidocaine injection;
0.2ml-1ml of epinephrine injection;
1ml-16ml of physiological saline injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210926222.0A CN115350199A (en) | 2022-08-03 | 2022-08-03 | Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210926222.0A CN115350199A (en) | 2022-08-03 | 2022-08-03 | Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115350199A true CN115350199A (en) | 2022-11-18 |
Family
ID=84033149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210926222.0A Pending CN115350199A (en) | 2022-08-03 | 2022-08-03 | Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115350199A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990118A (en) * | 2014-06-10 | 2014-08-20 | 温军海 | Combined reagent for treating hyperplasia caused by growth factor injection |
| CN104771440A (en) * | 2015-04-30 | 2015-07-15 | 青岛市市立医院 | Chinese and western medicine combined treatment method for scar hyperplasia |
| US20150273119A1 (en) * | 2014-03-26 | 2015-10-01 | Snu R&Db Foundation | Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating |
| CN107617107A (en) * | 2017-09-18 | 2018-01-23 | 浙江大学 | A kind of anti-scar preparation of compound Angiotensin-Converting class |
-
2022
- 2022-08-03 CN CN202210926222.0A patent/CN115350199A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150273119A1 (en) * | 2014-03-26 | 2015-10-01 | Snu R&Db Foundation | Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating |
| CN103990118A (en) * | 2014-06-10 | 2014-08-20 | 温军海 | Combined reagent for treating hyperplasia caused by growth factor injection |
| CN104771440A (en) * | 2015-04-30 | 2015-07-15 | 青岛市市立医院 | Chinese and western medicine combined treatment method for scar hyperplasia |
| CN107617107A (en) * | 2017-09-18 | 2018-01-23 | 浙江大学 | A kind of anti-scar preparation of compound Angiotensin-Converting class |
Non-Patent Citations (2)
| Title |
|---|
| 李超等: "病理性瘢痕注射治疗现状", 《中国医疗美容》, vol. 11, no. 1, pages 110 - 113 * |
| 林小龙等: "术后药物注射与放射治疗耳部瘢痕疙瘩的效果分析", 《现代中西医结合杂志》, vol. 24, no. 21, pages 2334 - 2336 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schlager et al. | Laser stimulation of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus surgery | |
| Saarilahti et al. | Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study | |
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| JP2008533140A (en) | Reduction of postoperative analgesics | |
| Bunyapraphatsara et al. | The efficacy of Aloe vera cream in the treatment of first, second and third degree burns in mice | |
| US8492435B2 (en) | Composition for treating a dermal anomaly | |
| US20210220260A1 (en) | Topical injectable composition | |
| KR101800851B1 (en) | Local anesthesia pain-relieving time-delay angent | |
| US12064404B2 (en) | Topical formulations and treatments | |
| JPH01503146A (en) | Methods of treating body tissue and administering medicines to body tissue | |
| KR101894521B1 (en) | Topical pharmaceutical composition for treating scar | |
| US10695356B2 (en) | Topical formulations efficacious for wound care | |
| CN115350199A (en) | Formula for dissolving scar tissue of growth factor hyperplasia and inhibiting growth | |
| US20030035847A1 (en) | Pharmacologically active strong acid solutions | |
| RU2528905C1 (en) | Method of soft tissue wound healing of various aetiology | |
| KR20200084814A (en) | Composition for lipolysis and cellulite improvement, and the kit comprising the same | |
| US10232004B2 (en) | Pharmaceutical composition based on Centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers | |
| CN104490870A (en) | Compound topical cream and application thereof | |
| RU2194537C2 (en) | Conservative method for treating urethral strictures | |
| CN108635362A (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN110063992A (en) | Burn and scald medication and preparation method thereof | |
| EP2883541B1 (en) | Composition for topical use comprising hyaluronic acid | |
| CN111346230B (en) | Pharmaceutical composition for rapidly relieving pain and swelling after operation and preparation method thereof | |
| Reihan et al. | Evaluation Of Intralesional Injection Of Botulinum Toxin Type A, Methotrexate, And Verapamil In Treatment Of Keloids: A Preliminary Study | |
| CN104887701A (en) | Novel fast hemorrhoid removal medicament, namely sodium sulfide-menthol composition and preparation method of novel fast hemorrhoid removal medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221118 |